

VECTOR MANUFACTURING

Full range of high-yield vector production scales

Center for Breakthrough Medicines (CBM) is an advanced therapy CDMO dedicated to partnering with our clients to deliver life-changing treatments to patients. Our state-of-the-art vector manufacturing facility benefits from full integration with all our services at a single site and is run by a world-class team of scientists and industry experts. We have over 20 suites focused on flexibility and scalability to support the production of Adeno-associated virus (AAV), Lentivirus (LVV), HSV, Adenovirus, and other novel viral-based therapeutics. Through our academic partnerships, our customers have access to the AAV platform from the lab that pioneered the first gene therapy.

CAPABILITIES AT OUR SINGLE SITE



20+
Vector
Suites



2,000 L+
Suspension
Process



15-30
Batches Annually
Per Suite

VECTOR MANUFACTURING

- AAV Vectors
- Adenoviral Vectors
- Novel-based Viral Therapeutics
- Lentiviral Vectors
- HSV Vectors

THE CBM DIFFERENCE

BLA-Ready High Throughput Suites

We offer turnkey expansion with modularly-designed, BLA-ready suites for high throughput and maximum yield.

Multi-Product Segregation

Our modern engineering and process controls - including single pass air and segregated processing suites - enable ultimate processing flexibility and reduce operational risk.

Onsite Drug Product Capabilities

We offer drug product capabilities onsite with higher performing fill lines and in-process testing to reduce risk of product loss.

Partner-in-Plant Model

We offer unparalleled flexibility to work alongside our subject matter experts in development labs and during GMP operations in our manufacturing suites.

Fit-for-Purpose Analytical Testing

Onsite testing capabilities support clinical and commercial GMP manufacturing from process development through drug substance manufacturing and drug product filling with release analytical testing panels customized for each vector batch.

Expert Team & Partners

The CBM team has direct, hands-on experience bringing the first cell and gene therapies to market at top-tier innovators and CDMOs, and our academic partners are pioneers in the field.